DDInter1484 DDInter875
Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Plicamycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gatifloxacin
Plicamycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Plicamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epoprostenol
Plicamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Plicamycin {u} may lead to a major life threatening interaction when taken with {v} Ibritumomab tiuxetan
Plicamycin {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Plicamycin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Plicamycin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Plicamycin may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan
Plicamycin may lead to a major life threatening interaction when taken with Regorafenib